metadata toggle
Pharmacological particulars
Pharmacotherapeutic group: Other ectoparasiticides for topical use.
ATC vet code: QP53AX24.
Pharmacodynamic properties
Dicyclanil prevents the moult from the first to the second larval instar of Lucilia spp. It is less effective against later larval stages and does not have any adulticide action. The mode of action of dicyclanil is believed to be similar to that of the triazine compounds.
Pharmacokinetic particulars
In studies with a more concentrated 5% (w/v) formulation, after 7 days post dosing, approximately 5% of the dose was absorbed and eliminated in urine and faeces. Peak blood levels were observed between 12 and 48h post dose, accounting for <0.025 mg dicyclanil equivalents/kg.
In experimental metabolism studies, absorbed radioactivity was widely distributed throughout the body. Longest half lives were found in liver and kidney being 13 and 10 days respectively. In muscle, fat and wool, unchanged dicyclanil was found to be the major residue, whereas in liver and kidney the descyclopropyl dicyclanil was found to be the major residue together with unchanged dicyclanil.
In field residue depletion studies on sheep with the veterinary medicinal product, residue levels at day 7 were very low (at maximum 31.9 and 30.7 µg/kg in liver and kidney, respectively, and no quantifiable residues found in muscle or fat), indicating minimal systemic absorption.
Environmental properties
The use of the veterinary medicinal product has harmful effects on dung flies and beetles.